The origin of circulating CD36 in type 2 diabetes

Nutrition and Diabetes

Volumn 3, Issue FEBRUARY, 2013, Pages

  Alkhatatbeh, M J ^a,b   Enjeti, A K ^b,c   Acharya, S ^d   Thorne, R F ^a,b   Lincz, L F ^b,c  

^a UNIVERSITY OF NEWCASTLE   (Australia)

^b HUNTER MEDICAL RESEARCH INSTITUTE   (Australia)

^c CALVARY MATER NEWCASTLE HOSPITAL   (Australia)

^d JOHN HUNTER HOSPITAL   (Australia)

Author keywords

Microparticles; Scavenger receptor; Soluble CD36; Type 2 diabetes mellitus

Indexed keywords

CD14 ANTIGEN; CD36 ANTIGEN; ENDOGLIN; HEMOGLOBIN A1C; PHOSPHATIDYLSERINE;

ADULT; APOPTOSIS; ARTICLE; CASE CONTROL STUDY; CLINICAL ARTICLE; CONTROLLED STUDY; EX VIVO STUDY; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; LEUKOCYTE COUNT; LIMIT OF DETECTION; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION;

EID: 84880561329     PISSN: None     EISSN: 20444052     Source Type: Journal    
DOI: 10.1038/nutd.2013.1     Document Type: Article

References (50)

1. Thorne RF, Mhaidat NM, Ralston KJ, Burns GF. CD36 is a receptor for oxidized high density lipoprotein: implications for the development of atherosclerosis. FEBS Lett 2007; 581: 1227-1232.
2. Silverstein RL. Inflammation, atherosclerosis, and arterial thrombosis: role of the scavenger receptor CD36. Cleve Clin J Med 2009; 76(Suppl 2): S27-S30.
3. Febbraio M, Hajjar DP, Silverstein RL. CD36: a class B scavenger receptor involved in angiogenesis, atherosclerosis, inflammation, and lipid metabolism. J Clin Invest 2001; 108: 785-791.
4. Susztak K, Ciccone E, McCue P, Sharma K, Bottinger EP. Multiple metabolic hits converge on CD36 as novel mediator of tubular epithelial apoptosis in diabetic nephropathy. PLoS Med 2005; 2: e45.
5. Handberg A, Levin K, Hojlund K, Beck-Nielsen H. Identification of the oxidized lowdensity lipoprotein scavenger receptor CD36 in plasma: a novel marker of insulin resistance. Circulation 2006; 114: 1169-1176.
6. Handberg A, Norberg M, Stenlund H, Hallmans G, Attermann J, Eriksson JW. Soluble CD36 (sCD36) clusters with markers of insulin resistance, and high sCD36 is associated with increased type 2 diabetes risk. J Clin Endocrinol Metab 2010; 95: 1939-1946.
7. Handberg A, Skjelland M, Michelsen AE, Sagen EL, Krohg-Sorensen K, Russell D et al. Soluble CD36 in plasma is increased in patients with symptomatic atherosclerotic carotid plaques and is related to plaque instability. Stroke 2008; 39: 3092-3095.
8. Glintborg D, Hojlund K, Andersen M, Henriksen JE, Beck-Nielsen H, Handberg A. Soluble CD36 and risk markers of insulin resistance and atherosclerosis are elevated in polycystic ovary syndrome and significantly reduced during pioglitazone treatment. Diabetes Care 2008; 31: 328-334.
9. Fernandez-Real JM, Handberg A, Ortega F, Hojlund K, Vendrell J, Ricart W. Circulating soluble CD36 is a novel marker of liver injury in subjects with altered glucose tolerance. J Nutr Biochem 2009; 20: 477-484.
10. Handberg A, Hojlund K, Gastaldelli A, Flyvbjerg A, Dekker JM, Petrie J et al. Plasma sCD36 is associated with markers of atherosclerosis, insulin resistance and fatty liver in a nondiabetic healthy population. J Intern Med 2012; 271: 294-304.
11. Gruarin P, Thorne RF, Dorahy DJ, Burns GF, Sitia R, Alessio M. CD36 is a ditopic glycoprotein with the N-terminal domain implicated in intracellular transport. Biochem Biophys Res Commun 2000; 275: 446-454.
12. Alkhatatbeh MJ, Mhaidat NM, Enjeti AK, Lincz LF, Thorne RF. The putative diabetic plasma marker, soluble CD36, is non-cleaved, non-soluble and entirely associated with microparticles. J Thromb Haemost 2011; 9: 844-851.
13. Little KM, Smalley DM, Harthun NL, Ley K. The plasma microparticle proteome. Semin Thromb Hemost 2010; 36: 845-856.
14. Burnier L, Fontana P, Kwak BR, Angelillo-Scherrer A. Cell-derived microparticles in haemostasis and vascular medicine. Thromb Haemost 2009; 101: 439-451.
15. Horstman LL, Ahn YS. Platelet microparticles: a wide-angle perspective. Crit Rev Oncol Hematol 1999; 30: 111-142.
16. Ratajczak J, Wysoczynski M, Hayek F, Janowska-Wieczorek A, Ratajczak MZ. Membrane-derived microvesicles: important and underappreciated mediators of cell-to-cell communication. Leukemia 2006; 20: 1487-1495.
17. Enjeti AK, Lincz LF, Seldon M. Microparticles in health and disease. Semin Thromb Hemost 2008; 34: 683-691.
18. Tan KT, Tayebjee MH, Lim HS, Lip GY. Clinically apparent atherosclerotic disease in diabetes is associated with an increase in platelet microparticle levels. Diabet Med 2005; 22: 1657-1662.
19. Mause SF, Weber C. Microparticles: protagonists of a novel communication network for intercellular information exchange. Circ Res. [Research Support, Non-U.S. Gov't Review] 2010; 107: 1047-1057.
20. Robert S, Poncelet P, Lacroix R, Arnaud L, Giraudo L, Hauchard A et al. Standardization of platelet-derived microparticle counting using calibrated beads and a Cytomics FC500 routine flow cytometer: a first step towards multicenter studies? J Thromb Haemost 2009; 7: 190-197.
21. Lacroix R, Robert S, Poncelet P, Kasthuri RS, Key NS, Dignat-George F. Standardization of platelet-derived microparticle enumeration by flow cytometry with calibrated beads: results of the International Society on Thrombosis and Haemostasis SSC Collaborative workshop. J Thromb Haemost 2010; 8: 2571-2574.
22. Thorne RF, Meldrum CJ, Harris SJ, Dorahy DJ, Shafren DR, Berndt MC et al. CD36 forms covalently associated dimers and multimers in platelets and transfected COS-7 cells. Biochem Biophys Res Commun 1997; 240: 812-818.
23. Dixon JB, O'Brien PE. Obesity and the white blood cell count: changes with sustained weight loss. Obes Surg 2006; 16: 251-257.
24. Pratley RE, Wilson C, Bogardus C. Relation of the white blood cell count to obesity and insulin resistance: effect of race and gender. Obes Res 1995; 3: 563-571.
25. Goichot B, Grunebaum L, Desprez D, Vinzio S, Meyer L, Schlienger JL et al. Circulating procoagulant microparticles in obesity. Diabetes Metab 2006; 32: 82-85.
26. Agouni A, Lagrue-Lak-Hal AH, Ducluzeau PH, Mostefai HA, Draunet-Busson C, Leftheriotis G et al. Endothelial dysfunction caused by circulating microparticles from patients with metabolic syndrome. Am J Pathol 2008; 173: 1210-1219.
27. Leroyer AS, Tedgui A, Boulanger CM. Microparticles and type 2 diabetes. Diabetes Metab 2008; 34(Suppl 1): S27-S32.
28. Tramontano AF, Lyubarova R, Tsiakos J, Palaia T, Deleon JR, Ragolia L. Circulating endothelial microparticles in diabetes mellitus. Mediators Inflamm 2010; 2010: 250476.
29. Omoto S, Nomura S, Shouzu A, Nishikawa M, Fukuhara S, Iwasaka T. Detection of monocyte-derived microparticles in patients with Type II diabetes mellitus. Diabetologia 2002; 45: 550-555.
30. Diamant M, Nieuwland R, Pablo RF, Sturk A, Smit JW, Radder JK. Elevated numbers of tissue-factor exposing microparticles correlate with components of the metabolic syndrome in uncomplicated type 2 diabetes mellitus. Circulation 2002; 106: 2442-2447.
31. Willekens FL, Bosch FH, Roerdinkholder-Stoelwinder B, Groenen-Dopp YA, Werre JM. Quantification of loss of haemoglobin components from the circulating red blood cell in vivo. Eur J Haematol 1997; 58: 246-250.
32. Willekens FLA, Werre JM, Groenen-Döpp YAM, Roerdinkholder- Stoelwinder B, De Pauw B. Bosman GJCGM. Erythrocyte vesiculation: a self-protective mechanism? Br J Haematol 2008; 141: 549-556.
33. Keymel S, Heiss C, Kleinbongard P, Kelm M, Lauer T. Impaired red blood cell deformability in patients with coronary artery disease and diabetes mellitus. Horm Metab Res 2011; 43: 760-765.
34. Bosman GJ, Lasonder E, Groenen-Dopp YA, Willekens FL, Werre JM, Novotny VM. Comparative proteomics of erythrocyte aging in vivo and in vitro. J Proteomics 2010; 73: 396-402.
35. Mallat Z, Benamer H, Hugel B, Benessiano J, Steg PG, Freyssinet JM et al. Elevated levels of shed membrane microparticles with procoagulant potential in the peripheral circulating blood of patients with acute coronary syndromes. Circulation 2000; 101: 841-843.
36. Sabatier F, Darmon P, Hugel B, Combes V, Sanmarco M, Velut J-G et al. Type 1 and type 2 diabetic patients display different patterns of cellular microparticles. Diabetes 2002; 51: 2840-2845.
37. Tsimerman G, Roguin A, Bachar A, Melamed E, Brenner B, Aharon A. Involvement of microparticles in diabetic vascular complications. Thromb Haemost 2011; 106: 310-321.
38. Helal O, Defoort C, Robert S, Marin C, Lesavre N, Lopez-Miranda J et al. Increased levels of microparticles originating from endothelial cells, platelets and erythrocytes in subjects with metabolic syndrome: relationship with oxidative stress. Nutr Metab Cardiovasc Dis 2011; 21: 665-671.
39. Jung KH, Chu K, Lee ST, Bahn JJ, Kim JH, Kim M et al. Risk of macrovascular complications in type 2 diabetes mellitus: endothelial microparticle profiles. Cerebrovasc Dis 2011; 31: 485-493.
40. Esposito K, Ciotola M, Giugliano D. Pioglitazone Reduces Endothelial Microparticles in the Metabolic Syndrome. Arterioscler Thromb Vasc Biol 2006; 26: 1926.
41. Mobarrez F, Egberg N, Antovic J, Bröijersen A, Jörneskog G, Walle'n H. Release of endothelial microparticles in vivo during atorvastatin treatment: a randomized double-blind placebo-controlled study. Thromb Res 2012; 129: 95-97.
42. Gonzalez-Quintero VH, Smarkusky LP, Jimenez JJ, Mauro LM, Jy W, Hortsman LL et al. Elevated plasma endothelial microparticles: preeclampsia versus gestational hypertension. Am J Obstet Gynecol 2004; 191: 1418-1424.
43. van Ierssel SH, Van Craenenbroeck EM, Conraads VM, Van Tendeloo VF, Vrints CJ, Jorens PG et al. Flow cytometric detection of endothelial microparticles (EMP): effects of centrifugation and storage alter with the phenotype studied. Thromb Res 2010; 125: 332-339.
44. Chmielewski M, Bragfors-Helin AC, Stenvinkel P, Lindholm B, Anderstam B. Serum soluble CD36, assessed by a novel monoclonal antibody-based sandwich ELISA, predicts cardiovascular mortality in dialysis patients. Clin Chim Acta 2010; 411: 2079-2082.
45. George J, Thoi L, McManus L, Reimann T. Isolation of human platelet membrane microparticles from plasma and serum. Blood 1982; 60: 834-840.
46. Ghosh A, Murugesan G, Chen K, Zhang L, Wang Q, Febbraio M et al. Platelet CD36 surface expression levels affect functional responses to oxidized LDL and are associated with inheritance of specific genetic polymorphisms. Blood 2011; 117: 6355-6366.
47. Love-Gregory L, Sherva R, Schappe T, Qi JS, McCrea J, Klein S et al. Common CD36 SNPs reduce protein expression and may contribute to a protective atherogenic profile. Hum Mol Genet 2011; 20: 193-201.
48. Mandosi E, Fallarino M, Gatti A, Carnovale A, Rossetti M, Lococo E et al. Atorvastatin downregulates monocyte CD36 expression, nuclear NFkappaB and TNFalpha levels in type 2 diabetes. J Atheroscler Thromb 2010; 17: 539-545.
49. Alexander Aguilera A, Herna'ndez Di'az G, Lara Barcelata M, Angulo Guerrero O, Oliart Ros RM. Induction of Cd36 expression elicited by fish oil PUFA in spontaneously hypertensive rats. J Nutr Biochemistry 2006; 17: 760-765.
50. Griffin E, Re A, Hamel N, Fu C, Bush H, McCaffrey T et al. A link between diabetes and atherosclerosis: glucose regulates expression of CD36 at the level of translation. Nat Med 2001; 7: 840-846.